Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1‐PDGFRA fusion transcript: extended follow‐up

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 145; no. 1; pp. 132 - 134
Main Authors Helbig, Grzegorz, Moskwa, Andrzej, Swiderska, Alina, Urbanowicz, Alina, Całbecka, Małgorzata, Gajkowska, Justyna, Zdziarska, Barbara, Brzeźniakiewicz, Katarzyna, Pogrzeba, Joanna, Krzemień, Sławomira
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.04.2009
Subjects
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Benzamides
chronic eosinophilic leukaemia
Drug Administration Schedule
Female
FIP1L1‐PDGFRA
Follow-Up Studies
Humans
Hypereosinophilic Syndrome - drug therapy
Hypereosinophilic Syndrome - genetics
imatinib
Imatinib Mesylate
Male
Middle Aged
mRNA Cleavage and Polyadenylation Factors
Oncogene Proteins, Fusion
Piperazines - therapeutic use
Pyrimidines - therapeutic use
Receptor, Platelet-Derived Growth Factor alpha
Young Adult
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2008.07546.x